货号:A286566 同义名: 依伐卡托 (VX-770) / VX-770
Ivacaftor is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | CFTR ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ataluren | ✔ | 98% | |||||||||||||||||
Lumacaftor |
++++
F508del-CFTR, EC50: 0.1 μM |
98% | |||||||||||||||||
CFTR(inh)-172 |
+++
CFTR, Ki: 300 nM |
99%+ | |||||||||||||||||
GlyH-101 |
+
CFTR, Ki: 4.3 μM |
99%+ | |||||||||||||||||
IOWH-032 |
++
CFTR, IC50: 1.01 μM |
99%+ | |||||||||||||||||
Tezacaftor | ✔ | 99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | Cystic fibrosis transmembrane conductance regulator (CFTR) is a protein kinase A-activated epithelial anion channel that is responsible for salt and fluid transport in multiple organs. Ivacaftor is a potent potentiator of CFTR. It increases forskolin-stimulated CFTR-mediated transepithelial current (IT) with an EC50 of 100 ± 47 nM in G551D-FRT cells. Also in F508del-FRT cells, ivacaftor increased forskolin-stimulated IT with an EC50 of 25 ± 5 nM. In recombinant cells expressing G551D-, F508del-, or wild-type (WT)-CFTR, 10 μM ivacaftor increased their CFTR channel open probability by ~6-fold, ~5-fold and ~2-fold, respectively. Treatment of ivacaftor significantly increased the forskolin-stimulated IT in F508del human bronchial epithelia (HBE) cells with an EC50 of 22 ± 10 nM. G551D/F508del HBE cells treated with 10μM ivacaftor for 5 days showed significant increased cilia beat frequency compared with vehicle-treated controls[1]. In the analysis of ATP-independent activity for WT-CFTR, 200 nM ivacaftor increased the activity by 2-fold, as determined by the ratio of post washout ATP-independent current to the robust ATP-induced current[2]. The bilayer studies of WT-CFTR showed that the open probability of CFTR channel treated with both 1 mM Mg-ATP and 2 μM ivacaftor was approximately twice that measured in the presence of Mg-ATP alone. The treatment of 10 μM ivacaftor on liposomes containing phosphorylated F508del-CFTR or phosphorylated G551D-CFTR increased iodide-mediated flux in the presence of 1 mM Mg-ATP[3]. |
作用机制 | Ivacaftor potentiates CFTR function by increasing the open time of WT-CFTR, stabilizing a post-hydrolytic open state, thereby promoting decoupling between the gating cycle and ATP hydrolysis cycle[2]. |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
CFBE41o- | 10 µM | Function Assay | induces robust increases in anion transport | 22768130 | |
HBE | 10 μM | Function Assay | 10 min | augments CFTR-dependent ion transport | 24106801 |
HBE | 10 µM | Function Assay | augments CFTR-dependent anion transport activity | 22768130 | |
HBE | 10 µM | Function Assay | 24 h | induces a modest but significant increase in ASL depth | 22768130 |
Dose | Rat: 10 mg/kg - 50 mg/kg[4] (p.o.) Dog: 60 mg/kg[4] (p.o.) |
Administration | p.o. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT03525548 | Cystic Fibrosis | Phase 3 | Active, not recruiting | March 2019 | - |
NCT03447249 | Cystic Fibrosis | Phase 3 | Active, not recruiting | April 16, 2019 | - |
NCT03525574 | Cystic Fibrosis | Phase 3 | Enrolling by invitation | June 2021 | - |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.55mL 0.51mL 0.25mL |
12.74mL 2.55mL 1.27mL |
25.48mL 5.10mL 2.55mL |
CAS号 | 873054-44-5 |
分子式 | C24H28N2O3 |
分子量 | 392.491 |
别名 | 依伐卡托 (VX-770) ;VX-770 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,2-8°C |
溶解度 |
DMSO: 50 mg/mL(127.39 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |
IP 2% DMSO+2% Tween80+40% PEG300+water 4 mg/mL clear PO 0.5% CMC-Na 38 mg/mL suspension |